Delhi: Delhi has recorded 7,486 new COVID-19 cases on November 18, taking the national capital’s infection tally to over 5 lakh. As of November 18, Delhi had recorded 5.03 lakh COVID-19 cases. This number includes 4.52 lakh recoveries. There were 42,458 ‘active’ COVID-19 cases in the National Capital.
Global Coronavirus impact & implecations
The Covid-19 Vaccine is set to touch the finish line with the First batch to be recieved only in December Next Month, thanks to their vaccine Pioneers Starting Production of their Candidates before receiving final approval.
However , Internationally , it is a vaccine candidate developed by the University of Oxford and AstraZeneca which is gaining more attention due to it’s size and geographical Spread, Here too AstraZeneca states that “Billions of Doses” of the candidate are already being Produced by December with the expected late trial data release.
WHO take on Covid-19 Vaccine
There are currently over 100 COVID-19 vaccine candidates with many of these in the human testing phase. The WHO is working closely with scientists, business and global health organizations through the ACT Accelerator to accelerate the epidemic response. When a safe and effective vaccine is found, COVAX (led by WHO, GAVI and CEPI) will facilitate the equal use and delivery of these vaccines for the protection of people in all countries. Most people at risk will be given priority.
Covid-19 Vaccine India:
India’s first COVID-19 vaccine has been approved for human trials by the country’s drug regulator, as the number of coronovirus-related cases and deaths continue to go up, a pharmaceutical company announced.
The vaccine named COVAXIN has been developed by Bharat Biotech Comnay in collaboration with the Indian Council of Medicine and the National Institute of Virology (NIV).
The indigenous, inactivated vaccine was developed from a SARS-CoV-2 strain, which was isolated by the NIV and transferred to the company’s BSL-3 High Containment facility located at Hyderabad city in southern India, Bharat Biotech said in a statement.
“Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic,” said Suchitra Ella, joint managing director of the company.
The permission to initiate Phase I & II Human clinical trials came after the company submitted results generated from preclinical studies, demonstrating safety and immune response.
Human clinical trials are scheduled to start across India in July.
How will the Priority be decided once, it clears all the formalities?
According to the Times of India, health and hygiene workers, police officers and elderly people with co-morbidities will receive the vaccine on priority.
The plan, which is still in the draft phase, aims to cover 23% of the population in the first phase. The final plan is likely to be ready by October-November, the report said.
Officials have said that giving the vaccine to India’s 1.3 billion people will be a mammoth exercise, likely to stretch well into 2022.
Among those who will be covered are 2 crore frontline workers, including 45 lakh police and 15 lakh people of the respective forces and armed forces. Municipal employees, public transport drivers, scavengers and teachers will also be given priority vaccinations.